FRESH TRACKS THERAPEUTICS IN (FRTX) Stock Analyst Earnings Estimates
NASDAQ:FRTX - Nasdaq - US10802T2042 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.82M -77.02% | 400K -78.02% | 6.94M 1,635.00% | 3.06M -55.91% | 6.12M 100.00% | |
| EBITDA YoY % growth | -20.97M -6.77% | -40.22M -91.80% | -21.5M 46.54% | N/A | N/A | |
| EBIT YoY % growth | -20.98M -6.66% | -40.24M -91.80% | -21.53M 46.50% | -23.169M -7.61% | N/A | |
| Operating Margin | -1,152.75% | -10,060.00% | -310.23% | -757.15% | N/A | |
| EPS YoY % growth | N/A | -23.85 26.82% | N/A 68.95% | -7.00 5.44% | -6.91 1.38% |
All data in USD
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.54 -20.32% | -1.72 -2.42% | -1.86 -8.33% | -1.10 -444.25% | -2.21 -43.71% |
| Revenue Q2Q % growth | 510K -75.12% | 510K 5,000.00% | 510K 920.00% | 4.59M -42.19% | 510K |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2023 Q2Q % growth | 0.32 115.46% | -0.61 | 0.93 | 152.29% |
| Q2 2023 Q2Q % growth | -17,036.00% | -1.71 | % | |
| Q1 2023 Q2Q % growth | 53.25% | -1.68 | % | |
| Q4 2022 Q2Q % growth | 52.59% | -1.28 | % | |
| Q3 2022 Q2Q % growth | -2.07 71.25% | -1.92 | -0.15 | -7.57% |
| Q2 2022 Q2Q % growth | -0.01 99.86% | -1.47 | 1.46 | 99.32% |
| Q1 2022 Q2Q % growth | -3.60 46.67% | -2.64 | -0.96 | -36.40% |
| Q4 2021 Q2Q % growth | -2.70 60.00% | -3.90 | 1.20 | 30.80% |
| Q3 2021 Q2Q % growth | -7.20 -6.67% | -5.74 | -1.46 | -25.49% |
| Q2 2021 Q2Q % growth | -7.20 | -5.74 | -1.46 | -25.49% |
| Q1 2021 Q2Q % growth | -6.75 | -5.28 | -1.47 | -27.88% |
| Q4 2020 Q2Q % growth | -6.75 | -4.13 | -2.62 | -63.40% |
| Q3 2020 Q2Q % growth | -6.75 | -8.49 | 1.74 | 20.51% |
| Q2 2019 Q2Q % growth | -34.65 | -35.34 | 0.69 | 1.96% |
| Q1 2019 Q2Q % growth | -66.15 | -57.83 | -8.32 | -14.38% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2023 Q2Q % growth | 7.94M 1,520.41% | 4.59M | 3.35M | 72.98% |
| Q2 2023 Q2Q % growth | 50K -98.84% | 510K | -460K | -90.20% |
| Q1 2023 Q2Q % growth | 10K -88.89% | 510K | -500K | -98.04% |
| Q4 2022 Q2Q % growth | 2.05M 1,950.00% | 2.295M | -245K | -10.68% |
| Q3 2022 Q2Q % growth | 490K 276.92% | 438.6K | 51.4K | 11.72% |
| Q2 2022 Q2Q % growth | 4.32M 2,780.00% | 3.198M | 1.122M | 35.08% |
| Q1 2022 Q2Q % growth | 90K 350.00% | 146.625K | -56.625K | -38.62% |
| Q4 2021 Q2Q % growth | 100K 233.33% | 157.845K | -57.845K | -36.65% |
| Q3 2021 Q2Q % growth | 130K -7.14% | 153K | -23K | -15.03% |
| Q2 2021 Q2Q % growth | 150K -75.41% | 51K | 99K | 194.12% |
| Q1 2021 Q2Q % growth | 20K -98.10% | 51K | -31K | -60.78% |
| Q4 2020 Q2Q % growth | 30K -95.52% | 510K | -480K | -94.12% |
| Q3 2020 Q2Q % growth | 140K -88.14% | 510K | -370K | -72.55% |
| Q2 2020 Q2Q % growth | 610K -76.26% | % | ||
| Q1 2020 Q2Q % growth | 1.05M -69.91% | % | ||
| Q2 2019 Q2Q % growth | 2.57M | 5.1K | 2.565M | 50,292.16% |
| Q1 2019 Q2Q % growth | 3.49M | 5.1K | 3.485M | 68,331.37% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | 0% |
| Revenue | 0% | 0% | 0% | 0% |